It's shaping up to be a tough period for Kindred Biosciences, Inc. (NASDAQ:KIN), which a week ago released some...
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2020 and provided updates on its programs. For the first quarter 2020, KindredBio reported net product revenues of $0.6 million and a net loss of $22.8 million, or $0.58 per share, which includes non-recurring charges of $5.1 million.
Q1 2020 Kindred Biosciences Inc Earnings Call
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront payment of $43 million and royalties on worldwide sales.
Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Bank of America Merrill Lynch Animal Health Summit on February 24 in New York City.
Kindred Biosciences (NASDAQ: KIN) will be releasing its next round of earnings this Monday, March 16. For all of the relevant information, here is your guide for Monday's Q4 earnings announcement.Earnings and Revenue Wall Street analysts see Kindred Biosciences reporting a loss of 36 cents per share on revenue of $1.3 million.View more earnings on KINKindred Biosciences reported a per-share loss of 46 cents when it published results during the same quarter last year. Sales in that period totaled $1.33 million. If the company were to match the consensus estimate when it reports Monday, EPS would have fallen 21.74%. Revenue would be down 1.96% on a year-over-year basis. Here's how the company's reported EPS has stacked up against analyst estimates in the past: Quarter Q3 2019 Q2 2019 Q1 2019 Q4 2018 EPS Estimate -0.370 -0.380 -0.410 -0.43 EPS Actual -0.390 -0.370 -0.420 -0.46 Stock Performance Shares of Kindred Biosciences were trading at $7.18 as of March 16. Over the last 52-week period, shares are down 22.04%. Given that these returns are generally negative, long-term shareholders are probably upset going into this earnings release. Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The popular rating by analysts on Kindred Biosciences stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.Conference Call Kindred Biosciences is scheduled to hold a conference call at 4:30 p.m. ET and can be accessed here: https://edge.media-server.com/mmc/p/umqkawy4See more from Benzinga * TransEnterix, Inc. Common Stock Earnings Preview * Stocks That Hit 52-Week Lows On Friday * Stocks That Hit 52-Week Highs On Friday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Q4 2019 Kindred Biosciences Inc Earnings Call
Kindred Biosciences, Inc. (NASDAQ:KIN) shareholders should be happy to see the share price up 26% in the last month...
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has completed the sale of Mirataz® to Dechra Pharmaceuticals PLC (LSE: DPH) for an upfront payment of $43 million, and royalties on worldwide sales.
Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its fourth quarter and year-end 2019 financial results on March 16, 2020, after the market close. The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day.
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company developing novel biologics, today announced it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT) for the manufacture of Vaxart's oral vaccine candidate for COVID-19.
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2020 Virtual Jaws & Paws Conference on May 27.
NEW YORK, NY / ACCESSWIRE / March 16, 2020 / Kindred Biosciences, Inc. (NASDAQ:KIN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 16, 2020 at ...
Kindred Bio (KIN) delivered earnings and revenue surprises of -5.26% and -3.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from its pilot field efficacy study of KIND-025, a canine fusion protein targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), for the treatment of atopic dermatitis in dogs.
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
One of the biggest stories of last week was how Kindred Biosciences, Inc. (NASDAQ:KIN) shares plunged 47% in the week...
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its first quarter 2020 financial results on May 7, 2020, after the market close. The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day.
For a description of important factors that could cause actual results to differ, we refer you to the forward-looking statements in today's press release and the note on forward-looking statements in the company's SEC filings. It is now my pleasure to turn the call over to Kindred Bio's CEO, Richard Chin. Dr. Chin, please proceed.